Evidence map›Paper›PMID 36204364›Full record

ArticleCurrent urology2022

How to reduce bacillus Calmette-Guérin discontinuation in patients with severe functional impairment.

Luca Di Gianfrancesco, Mauro Ragonese, Massimiliano Foti, Giuseppe Palermo, Emilio Sacco, PierFrancesco Bassi, Marco Racioppi

Open access · diamondAbstract read
In one paragraph

Article in Current urology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it, 2 citations in OpenAlex.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Luca Di GianfrancescoClinica Urologica, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS-Università Cattolica del Sacro Cuore di Roma, Rome, Italy.
Mauro RagoneseClinica Urologica, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS-Università Cattolica del Sacro Cuore di Roma, Rome, Italy.
Massimiliano FotiClinica Urologica, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS-Università Cattolica del Sacro Cuore di Roma, Rome, Italy.
Giuseppe PalermoClinica Urologica, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS-Università Cattolica del Sacro Cuore di Roma, Rome, Italy.
Emilio SaccoClinica Urologica, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS-Università Cattolica del Sacro Cuore di Roma, Rome, Italy.
PierFrancesco BassiClinica Urologica, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS-Università Cattolica del Sacro Cuore di Roma, Rome, Italy.
Marco RacioppiClinica Urologica, Fondazione Policlinico Universitario "Agostino Gemelli" IRCCS-Università Cattolica del Sacro Cuore di Roma, Rome, Italy.
Università Cattolica del Sacro Cuore · ITAgostino Gemelli University Polyclinic · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Severe functional impairment is often considered a contraindication to intravesical therapy for nonmuscle-invasive bladder cancer (NMIBC). A tailored intravesical bacillus Calmette-Guérin (BCG) procedure was evaluated in high-risk (HR)-NMIBC patients with severe functional impairment. Materials and methods: Patients with a Katz Index score of 2 or less and an initial diagnosis of HR-NMIBC with atraumatic insertion of a Foley-type indwelling catheter, bladder emptying, and BCG instillation were prospectively treated; after 2 hours, the bladder was emptied and the catheter was removed (group A).After propensity score matching, 52 patients in group A were compared with that of 52 consecutive patients in group B using a retrospective database, with similar baseline/oncological characteristics and treated with standard intermittent catheterization. Moreover, groups A and B were compared with that of 130 consecutive patients (group C) retrospectively evaluated, with similar oncological characteristics but with a Katz Index score of 3 or greater and treated with standard intermittent catheterization. Results: The discontinuation rates were 11.5%, 35%, and 9% in groups A, B, and C, respectively (A vs. B, log-rank score 42.52 [ Conclusions: A tailored intravesical instillation procedure may reduce BCG discontinuation and adverse effects.

Indexed as

Adverse eventDiscontinuation rateIntravesical bacillus Calmette-GuérinSevere functional impairmentTailored procedure

Identifiers

PMID36204364
PMCPMC9527929
OpenAlexW4293125335

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.